The effect of myofascial release in patients with breast cancer-related lymphedema: a cross-over randomized controlled trial.

Lymphedema after breast cancer treatment causes swelling and discomfort that physiotherapists often try to manage with complete decongestive therapy, and this trial asked whether adding myofascial release, a manual soft-tissue technique, offers any extra benefit over a placebo version of the same hands-on contact. Thirty patients took part in a crossover design, each receiving both real and placebo myofascial release for four weeks apiece, separated by a washout period, always alongside standard decongestive therapy. Arm volume improved significantly during both the real and placebo treatment periods, but the two were not statistically different from each other, meaning the volume reduction cannot be clearly attributed to the myofascial technique itself. Secondary measures, including pain, shoulder range of motion, and shoulder function, showed greater improvement with real myofascial release than placebo.

The trial was small, and because the placebo also involved therapist contact and movement, expectation and attention may have contributed to the shared benefit seen in both groups.

If you have swelling in your arm after breast cancer treatment, a common approach called complete decongestive therapy is often used alongside hands-on techniques like myofascial release, which involves manipulating soft tissue. This study looked at whether adding real myofascial release, compared with a placebo version of the same hands-on treatment, made an extra difference to arm swelling, pain, and shoulder movement. Both the real and placebo treatments were followed by reduced arm swelling, but there was no clear difference between them, so the swelling improvement cannot be confidently credited to the myofascial technique specifically.

On the other hand, people reported less pain and better shoulder movement and function with the real treatment compared with placebo, which is encouraging but comes from a small study of only thirty people. Because the placebo also involved hands-on contact and attention from a therapist, some of the shared benefit could reflect that experience rather than the specific technique. This research gives an early, limited picture rather than a settled answer.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

The clinical question here is whether myofascial release adds measurable benefit over sham manual contact when layered onto complete decongestive therapy for breast cancer-related lymphedema. In this crossover trial of 30 patients, upper limb volume improved significantly within both the MFR period and the placebo MFR period, with no statistically significant between-treatment difference, so a specific volume-reduction effect from MFR was not established.

Secondary outcomes, including subjective pain, shoulder range of motion (except internal rotation), and shoulder function, favored MFR over placebo. This sharpens expectations around what manual myofascial technique may and may not contribute: it does not appear to offer a demonstrable edge for reducing limb volume beyond placebo contact, but it may inform discussion about pain and mobility outcomes, which were secondary and derived from a small, single-blinded sample. Because the placebo arm involved comparable therapist contact time, attention and expectation effects cannot be ruled out as contributors to the secondary-outcome differences, and the trial's size limits how far these findings generalize.